Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | FSHR | P23945 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267682 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2MAP3K5NPC1RAB9APOLB | |
| SCHEMBL14019178 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2MAP3K5NPC1RAB9APOLB | |
| SCHEMBL14108672 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2MAP3K5NPC1RAB9APOLB | |
| SCHEMBL14108669 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2MAP3K5NPC1RAB9APOLB | |
| SCHEMBL30617073 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2MAP3K5NPC1RAB9APOLB | |
| SCHEMBL14019177 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9APOLBPTGER1 | |
| SCHEMBL4759503 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APOLBMGLL | |
| SCHEMBL14019193 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2MAP3K5PTGER1ALDH1A1HSD17B10 | |
| SCHEMBL589478 | 0.76 | PTGER1 (0.46) | SMN1; SMN2POLBPTGER1MGLLALDH1A1 | |
| SCHEMBL3719046 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2MAP3K5NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1469856-A4 | 8-HETEROARYL XANTHINE ADENOSINE A SB 2B /SB RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RES & DEV (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1469856-A2 | 8-HETEROARYL XANTHINE ADENOSINE A SB 2B /SB RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003063800-A2 | 8-HETEROARYL XANTHINE ADENOSINE A2B RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0722446-B1 | DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS | PHARMACIA ITALIA SPA (IT) | 2002-12-11 | — | — | EP | disclosed |
| US-5753629-A | AMINO ACID DERIVATIVE ANTIBIOTICS; VIRICIDES | PHARMACIA S.P.A. (IT) | 1998-05-19 | — | — | US | disclosed |
| EP-0722446-A1 | DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-07-24 | — | — | EP | disclosed |
| WO-1996005196-A1 | DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS | PHARMACIA S.P.A. (IT) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | SMN1; SMN2 3347/4885MAP3K5 3274/4885NPC1 1536/4885 |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | SMN1; SMN2 2803/4885MAP3K5 3127/4885NPC1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.